Photocure ASA (OSL:PHO)

Market Cap	1.57B +1.3%
Revenue (ttm)	532.58M +1.4%
Net Income	-1.52M
EPS	-0.06
Shares Out	26.61M
PE Ratio	n/a
Forward PE	236.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,165
Average Volume	50,761
Open	59.00
Previous Close	59.00
Day's Range	58.50 - 59.60
52-Week Range	47.60 - 79.80
Beta	0.37
RSI	21.92
Earnings Date	Feb 18, 2026

About Photocure ASA

Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreemen...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1993
• Employees: 101
• Stock Exchange: Oslo Børs
• Ticker Symbol: PHO

Financial Performance

In 2025, Photocure ASA's revenue was 532.58 million, an increase of 1.37% compared to the previous year's 525.39 million. Losses were -1.52 million, -54.52% less than in 2024.